The global market for Dendritic Cell Vaccine was valued at US$ 68.9 million in the year 2024 and is projected to reach a revised size of US$ 85 million by 2031, growing at a CAGR of 3.1% during the forecast period.
Dendritic cells (DCs) have several characteristics that make them an ideal vehicle for tumor vaccines, and with the first US FDA-approved DC-based vaccine in use for the treatment of prostate cancer, this technology has become a promising new therapeutic option.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Dendritic Cell Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dendritic Cell Vaccine.
The Dendritic Cell Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dendritic Cell Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dendritic Cell Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
3M
Activarti
Argos Therapeutics
Batavia Bioservices
Bellicum Pharmaceuticals
Creagene
DanDrit Biotech
DCPrime
Sanpower Corporation (Dendreon Corporation)
Elios Therapeutics
ImmunoCellular Therapeutics
Immunicum
Kiromic
Medigene
Merck & Co.
Segment by Type
Non-Targeted
Target
Segment by Application
Covid-19
Cancer
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dendritic Cell Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dendritic Cell Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Dendritic Cell Vaccine 麻豆原创 Overview
1.1 Product Definition
1.2 Dendritic Cell Vaccine by Type
1.2.1 Global Dendritic Cell Vaccine 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Non-Targeted
1.2.3 Target
1.3 Dendritic Cell Vaccine by Application
1.3.1 Global Dendritic Cell Vaccine 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Covid-19
1.3.3 Cancer
1.3.4 Others
1.4 Global Dendritic Cell Vaccine 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Dendritic Cell Vaccine Revenue 2020-2031
1.4.2 Global Dendritic Cell Vaccine Sales 2020-2031
1.4.3 Global Dendritic Cell Vaccine 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Dendritic Cell Vaccine 麻豆原创 Competition by Manufacturers
2.1 Global Dendritic Cell Vaccine Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Dendritic Cell Vaccine Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Dendritic Cell Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Dendritic Cell Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Dendritic Cell Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dendritic Cell Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Dendritic Cell Vaccine, Date of Enter into This Industry
2.8 Global Dendritic Cell Vaccine 麻豆原创 Competitive Situation and Trends
2.8.1 Global Dendritic Cell Vaccine 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Dendritic Cell Vaccine Players 麻豆原创 Share by Revenue
2.8.3 Global Dendritic Cell Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Dendritic Cell Vaccine 麻豆原创 Scenario by Region
3.1 Global Dendritic Cell Vaccine 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Dendritic Cell Vaccine Sales by Region: 2020-2031
3.2.1 Global Dendritic Cell Vaccine Sales by Region: 2020-2025
3.2.2 Global Dendritic Cell Vaccine Sales by Region: 2026-2031
3.3 Global Dendritic Cell Vaccine Revenue by Region: 2020-2031
3.3.1 Global Dendritic Cell Vaccine Revenue by Region: 2020-2025
3.3.2 Global Dendritic Cell Vaccine Revenue by Region: 2026-2031
3.4 North America Dendritic Cell Vaccine 麻豆原创 Facts & Figures by Country
3.4.1 North America Dendritic Cell Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Dendritic Cell Vaccine Sales by Country (2020-2031)
3.4.3 North America Dendritic Cell Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Dendritic Cell Vaccine 麻豆原创 Facts & Figures by Country
3.5.1 Europe Dendritic Cell Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Dendritic Cell Vaccine Sales by Country (2020-2031)
3.5.3 Europe Dendritic Cell Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dendritic Cell Vaccine 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Dendritic Cell Vaccine 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Dendritic Cell Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Dendritic Cell Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Dendritic Cell Vaccine 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Dendritic Cell Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Dendritic Cell Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Dendritic Cell Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dendritic Cell Vaccine 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Dendritic Cell Vaccine 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Dendritic Cell Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Dendritic Cell Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Dendritic Cell Vaccine Sales by Type (2020-2031)
4.1.1 Global Dendritic Cell Vaccine Sales by Type (2020-2025)
4.1.2 Global Dendritic Cell Vaccine Sales by Type (2026-2031)
4.1.3 Global Dendritic Cell Vaccine Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Dendritic Cell Vaccine Revenue by Type (2020-2031)
4.2.1 Global Dendritic Cell Vaccine Revenue by Type (2020-2025)
4.2.2 Global Dendritic Cell Vaccine Revenue by Type (2026-2031)
4.2.3 Global Dendritic Cell Vaccine Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Dendritic Cell Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Dendritic Cell Vaccine Sales by Application (2020-2031)
5.1.1 Global Dendritic Cell Vaccine Sales by Application (2020-2025)
5.1.2 Global Dendritic Cell Vaccine Sales by Application (2026-2031)
5.1.3 Global Dendritic Cell Vaccine Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Dendritic Cell Vaccine Revenue by Application (2020-2031)
5.2.1 Global Dendritic Cell Vaccine Revenue by Application (2020-2025)
5.2.2 Global Dendritic Cell Vaccine Revenue by Application (2026-2031)
5.2.3 Global Dendritic Cell Vaccine Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Dendritic Cell Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 3M
6.1.1 3M Company Information
6.1.2 3M Description and Business Overview
6.1.3 3M Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 3M Dendritic Cell Vaccine Product Portfolio
6.1.5 3M Recent Developments/Updates
6.2 Activarti
6.2.1 Activarti Company Information
6.2.2 Activarti Description and Business Overview
6.2.3 Activarti Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Activarti Dendritic Cell Vaccine Product Portfolio
6.2.5 Activarti Recent Developments/Updates
6.3 Argos Therapeutics
6.3.1 Argos Therapeutics Company Information
6.3.2 Argos Therapeutics Description and Business Overview
6.3.3 Argos Therapeutics Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Argos Therapeutics Dendritic Cell Vaccine Product Portfolio
6.3.5 Argos Therapeutics Recent Developments/Updates
6.4 Batavia Bioservices
6.4.1 Batavia Bioservices Company Information
6.4.2 Batavia Bioservices Description and Business Overview
6.4.3 Batavia Bioservices Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Batavia Bioservices Dendritic Cell Vaccine Product Portfolio
6.4.5 Batavia Bioservices Recent Developments/Updates
6.5 Bellicum Pharmaceuticals
6.5.1 Bellicum Pharmaceuticals Company Information
6.5.2 Bellicum Pharmaceuticals Description and Business Overview
6.5.3 Bellicum Pharmaceuticals Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bellicum Pharmaceuticals Dendritic Cell Vaccine Product Portfolio
6.5.5 Bellicum Pharmaceuticals Recent Developments/Updates
6.6 Creagene
6.6.1 Creagene Company Information
6.6.2 Creagene Description and Business Overview
6.6.3 Creagene Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Creagene Dendritic Cell Vaccine Product Portfolio
6.6.5 Creagene Recent Developments/Updates
6.7 DanDrit Biotech
6.7.1 DanDrit Biotech Company Information
6.7.2 DanDrit Biotech Description and Business Overview
6.7.3 DanDrit Biotech Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 DanDrit Biotech Dendritic Cell Vaccine Product Portfolio
6.7.5 DanDrit Biotech Recent Developments/Updates
6.8 DCPrime
6.8.1 DCPrime Company Information
6.8.2 DCPrime Description and Business Overview
6.8.3 DCPrime Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 DCPrime Dendritic Cell Vaccine Product Portfolio
6.8.5 DCPrime Recent Developments/Updates
6.9 Sanpower Corporation (Dendreon Corporation)
6.9.1 Sanpower Corporation (Dendreon Corporation) Company Information
6.9.2 Sanpower Corporation (Dendreon Corporation) Description and Business Overview
6.9.3 Sanpower Corporation (Dendreon Corporation) Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sanpower Corporation (Dendreon Corporation) Dendritic Cell Vaccine Product Portfolio
6.9.5 Sanpower Corporation (Dendreon Corporation) Recent Developments/Updates
6.10 Elios Therapeutics
6.10.1 Elios Therapeutics Company Information
6.10.2 Elios Therapeutics Description and Business Overview
6.10.3 Elios Therapeutics Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Elios Therapeutics Dendritic Cell Vaccine Product Portfolio
6.10.5 Elios Therapeutics Recent Developments/Updates
6.11 ImmunoCellular Therapeutics
6.11.1 ImmunoCellular Therapeutics Company Information
6.11.2 ImmunoCellular Therapeutics Description and Business Overview
6.11.3 ImmunoCellular Therapeutics Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 ImmunoCellular Therapeutics Dendritic Cell Vaccine Product Portfolio
6.11.5 ImmunoCellular Therapeutics Recent Developments/Updates
6.12 Immunicum
6.12.1 Immunicum Company Information
6.12.2 Immunicum Description and Business Overview
6.12.3 Immunicum Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Immunicum Dendritic Cell Vaccine Product Portfolio
6.12.5 Immunicum Recent Developments/Updates
6.13 Kiromic
6.13.1 Kiromic Company Information
6.13.2 Kiromic Description and Business Overview
6.13.3 Kiromic Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Kiromic Dendritic Cell Vaccine Product Portfolio
6.13.5 Kiromic Recent Developments/Updates
6.14 Medigene
6.14.1 Medigene Company Information
6.14.2 Medigene Description and Business Overview
6.14.3 Medigene Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Medigene Dendritic Cell Vaccine Product Portfolio
6.14.5 Medigene Recent Developments/Updates
6.15 Merck & Co.
6.15.1 Merck & Co. Company Information
6.15.2 Merck & Co. Description and Business Overview
6.15.3 Merck & Co. Dendritic Cell Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Merck & Co. Dendritic Cell Vaccine Product Portfolio
6.15.5 Merck & Co. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dendritic Cell Vaccine Industry Chain Analysis
7.2 Dendritic Cell Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dendritic Cell Vaccine Production Mode & Process Analysis
7.4 Dendritic Cell Vaccine Sales and 麻豆原创ing
7.4.1 Dendritic Cell Vaccine Sales Channels
7.4.2 Dendritic Cell Vaccine Distributors
7.5 Dendritic Cell Vaccine Customer Analysis
8 Dendritic Cell Vaccine 麻豆原创 Dynamics
8.1 Dendritic Cell Vaccine Industry Trends
8.2 Dendritic Cell Vaccine 麻豆原创 Drivers
8.3 Dendritic Cell Vaccine 麻豆原创 Challenges
8.4 Dendritic Cell Vaccine 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
3M
Activarti
Argos Therapeutics
Batavia Bioservices
Bellicum Pharmaceuticals
Creagene
DanDrit Biotech
DCPrime
Sanpower Corporation (Dendreon Corporation)
Elios Therapeutics
ImmunoCellular Therapeutics
Immunicum
Kiromic
Medigene
Merck & Co.
听
听
*If Applicable.